

## [Betamethasone](#)

Essential medicine status

Section:

[13. Dermatological medicines](#) [13.3. Dermatological medicines > Anti-inflammatory and antipruritic medicines](#)

ATC codes: [D07AC01](#)

EMLc

Indication

Psoriasis of unspecified type ICD11 code: [EA90.Z](#)

INN

Betamethasone

Medicine type

Chemical agent

List type

Core

Formulations

**Local > Topical > Cream:** 0.1% (as valerate)

**Local > Topical > Ointment:** 0.1% (as valerate)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 2007 ([TRS 950](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Also recommended for children

Age restriction

Hydrocortisone preferred in neonates.

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup:D07AC Corticosteroids, potent (group III).

Therapeutic alternatives limitations for EMLc

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup:D07AC Corticosteroids, potent (group III).

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Betamethasone](#)

[DrugBank](#)

[Betamethasone](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, D07AC Corticosteroids, potent (group III), be specified as therapeutic alternatives under the square box listing for betamethasone on the EML and EMLc.